The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
Roger S McIntyre1,2 1Department of Psychiatry, University of Toronto, 2Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Abstract: Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, eff...
Enregistré dans:
Auteur principal: | McIntyre RS |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d40558993d764a58a049ed3e652c0a7d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
par: Xin KZ, et autres
Publié: (2019) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
par: Zhong Z, et autres
Publié: (2017) -
The noradrenergic paradox: implications in the management of depression and anxiety
par: Montoya A, et autres
Publié: (2016) -
Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
par: Yuan H, et autres
Publié: (2019) -
Effect of Depression and Antidepressants on Sexual Dysfunction in Men with Diabetes: A National Population-Based Cohort Study
par: Chung PL, et autres
Publié: (2020)